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Purpose: To identify baseline characteristics that predict the number of treatments with 
 intravitreal triamcinolone acetonide (IVTA) plus laser photocoagulation needed to treat diabetic 
macular edema over a 2-year period.
Methods: Individual data from 42 eyes of 42 participants treated with IVTA plus laser pho-
tocoagulation for diabetic macular edema during a prospective, randomized, double-masked, 
placebo-controlled trial were used for this post hoc analysis. Baseline characteristics – age, 
gender, best-corrected visual acuity, glycosylated hemoglobin, phakic status, intraocular pres-
sure, and central macular thickness (CMT) – were correlated with the number of IVTA plus 
laser treatments received during the 2 years of this study.
Results: The median number of treatments received over the 2-year period was 2.5 (interquartile 
range 1.0–3.0), with 21 (50%) eyes needing three or more treatments. Eyes that received 
more IVTA plus laser treatments had a higher mean baseline CMT and eyes with a higher 
baseline CMT were more likely to receive three or more treatments (odds ratio 5.13, 95% 
confidence interval 1.75–15.04, P=0.003 per 100 µm increase in CMT). No significant rela-
tionship was found between other baseline characteristics and the number of IVTA plus laser 
treatments received.
Conclusion: Higher baseline CMT was strongly linked with receiving more IVTA plus laser 
treatments. These patients may be at higher risk of developing dose-dependent steroid-related 
adverse events, cataract progression, and intraocular pressure rise.
Keywords: diabetic macular edema, intravitreal triamcinolone, central macular thickness
Introduction
Diabetic retinopathy is the leading cause of blindness in working-age persons around 
the world.1,2 It can be found in three out of four patients within 15 years of the diag-
nosis of diabetes.3,4 Visual impairment is most commonly a consequence of diabetic 
macular edema (DME).5,6 While vascular endothelial growth factor inhibitors are 
usually used first for DME, intravitreal triamcinolone acetonide monotherapy (IVTA) 
has also been proven to be efficacious for refractory DME and vision loss in eyes that 
fail laser therapy.1,7 It has been shown to improve vision and reduce central macular 
thickness (CMT), with benefits persisting for up to 5 years.8–10 Moreover, for patients 
with earlier DME, IVTA followed by laser photocoagulation has been shown to double 
the chance of an improvement in vision by ten or more best-corrected logarithm of 
minimum angle of resolution letters at 2 years compared to laser alone.11 This result 
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can be contrasted with the Diabetic Retinopathy Clinical 
Research Network trial, which found that only the subset 
of eyes that were pseudophakic at baseline had better visual 
acuity outcomes after IVTA combined with prompt laser 
treatment.12 The divergent findings may in part be due to 
differences in study protocol, ie, the shorter period of time 
between IVTA and laser therapy in the Diabetic Retinopathy 
Clinical Research Network study (3–10 days versus 6 weeks) 
may not have allowed sufficient time for the edema to resolve 
before application of the laser.11,12
Since patients often require more than one injection 
with IVTA, they may be at higher risk of dose-dependent 
steroid-related adverse events, principally cataract and 
raised intraocular pressure (IOP).13–15 This paper examines 
whether it is possible to predict from baseline characteristics 
the number of IVTA injections patients will require once 
they embark on a course of combined therapy with laser 
photocoagulation.
Materials and methods
This analysis was based on data from the THUNDERBIRD 
(A Multicenter Randomized Clinical Trial of Laser Treat-
ment Plus IVTA for DME) study, a prospective, random-
ized, double-masked, placebo-controlled trial.11,16 The 
THUNDERBIRD study tested the hypothesis that there is 
a synergistic effect of IVTA and laser photocoagulation on 
vision improvement and reduction in macular thickness in 
eyes with DME. The study was conducted in accordance 
with the Declaration of Helsinki and was approved by 
the Research Ethics Committees of the four participating 
clinical centers. Patients were included in the THUNDER-
BIRD study if they had focal or diffuse DME involving 
the central fovea with a CMT of greater than 250 µm and 
best-corrected logarithm of minimum angle of resolution 
letters read (ie, best-corrected visual acuity [BCVA]) in 
the affected eye(s) of 17–70 letters.  Time-domain optical 
coherence tomography was performed (Stratus OCT™; 
Carl Zeiss Meditec, Jena, Germany) to determine the aver-
age thickness of the central macula (1 mm diameter). Eyes 
were allocated either to IVTA injection or sham-injection 
6 weeks prior to laser photocoagulation. Eyes assigned 
to IVTA received an intravitreal injection of 0.1 mL of 
Kenacort® 40 (40 mg/mL triamcinolone acetonide; Bristol-
Myers Squibb, New York, NY, USA). Eyes assigned to 
placebo were prepared in the same way but had the barrel 
of the syringe without a needle pushed firmly against the 
eye to simulate an injection.
Retreatment with injection of study medication followed 
by laser photocoagulation was considered at the discretion 
of the chief investigator at each site at each visit, as long as 
treatments were at least 6 months apart, unless any of the 
following were present:
•	 The investigator considered the macula nearly flat and 
central optical coherence tomography thickness was 
,300 µm;
•	 BCVA was 79 letters or better (20/25) or BCVA had 
improved by five letters or more compared with the best 
BCVA after treatment or baseline acuity; or
•	 Laser treatment was considered by investigator as 
 “inappropriate” or had no potential for improvement.
Only eyes that received IVTA in these studies were 
included in this analysis. Further details on patient enrolment, 
sample size calculation, treatment assignment, data collec-
tion and masking, treatment, and outcomes can be found in 
previously published reports of this trial.11,16
Statistical analysis
Data are presented as the mean ± standard deviation when 
normally distributed or as median (interquartile range) if not. 
Normality was assessed using the Shapiro–Wilk test.
The analysis of the factors predictive of the extent of 
IVTA plus laser treatment was not a prospectively defined 
outcome of the study. There was a potential maximum of 
five treatments per participant over the 2 years. Eyes were 
analyzed according to the number of treatments they received: 
one versus two versus three versus four or five. For the 
purposes of a binary logistic regression analysis, eyes were 
classified as having either received few (one or two) or many 
(three or more) treatments.
Differences in continuous variables between multiple 
groups were compared using an analysis of variance or the 
Kruskal–Wallis test for normally and not normally distrib-
uted data, respectively. In cases of significant analysis of 
variance results, post hoc testing was performed. If equal 
variances could be assumed, a Bonferroni correction was 
applied. If not, Dunn’s test was applied. The homogeneity 
of variances was assessed using Levene’s test. Differences 
in proportions between multiple groups were analyzed using 
the chi-squared test.
The measured baseline characteristics were age, gender, 
BCVA, glycosylated hemoglobin (HbA
1c
), phakic status, 
IOP, and CMT.
To analyze the predictive value of baseline character-
istics on the number of treatments received, binary logistic 
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regression and multinomial logistic regression models 
were applied. Eyes with missing values were excluded 
from these analyses. For these, the dependent variable was 
the number of treatments received, classified as described 
above. The independent variables were the baseline 
 characteristics. Gender (female = reference category) and 
phakia  (pseudophakic = reference category) were defined 
as categorical variables. All other independent variables 
were defined as continuous variables. For the regression 
analyses, baseline CMT was divided by 100. The resulting 
odds ratios were per 100 µm difference in baseline CMT. 
Since the a priori risk of retreatment was not known, a Cox 
regression was performed in addition to the logistic regres-
sion analyses.
An a priori P-value of ,0.05 was defined as statistically 
significant. All data were analyzed using a commercially 
available software package (SPSS® 21; IBM Corporation, 
Armonk, NY, USA).
Results
Of the 42 eyes treated with IVTA plus laser photocoagulation 
in the  THUNDERBIRD study, 14 (33%) were pseudophakic 
at baseline and 16 (38%) patients were female. The mean age 
at baseline was 66.8±10.4 years, IOP was 16.1±3.0 mmHg, 
and CMT was 482±123 µm. The median baseline BCVA was 
57 (53–70) letters and HbA
1c
 was 7.6% (7.2%–9.4%). Data 
for the measured baseline characteristics were complete, 
except for one eye with no recorded HbA
1c
 value.
A total of 101 IVTA plus laser treatments were given dur-
ing the 2 years of this study. The median number of treatments 
was 2.5 (1.0–3.0). Only one treatment was required in eleven 
(26%) eyes, two in ten (24%) eyes, three in 14 (33%) eyes, 
four in seven (17%) eyes, and five in zero (0%) eyes.
Table 1 Baseline characteristics and visual outcomes of eyes treated with intravitreal triamcinolone acetonide stratified with respect 
to number of intravitreal triamcinolone acetonide plus laser treatments received
One treatment 
(n=11)
Two treatments 
(n=10)
Three treatments 
(n=14)
Four treatments 
(n=7)
P-value
Baseline characteristics 
 Age, years 
 Female gender, n (%) 
 BCVA, logMAR letters read 
 HbA1c, %
† 
 Pseudophakic, n (%) 
 IOP, mmHg 
 CMT, µm
 
64.8±9.3 
4 (37%) 
59.0±9.2 
7.1 (6.3–8.88) 
3 (27%) 
16.0 (16.0–18.0) 
387±87
 
69.3±15.5 
4 (40%) 
55.7±15.0 
7.6 (7.1–7.9) 
4 (40%) 
18.5 (12.0–21.0) 
438±102
 
67.4±8.5 
7 (50%) 
50.4±13.7 
7.9 (6.6–9.4) 
6 (43%) 
15.0 (14.0–16.0) 
554±114
 
65.1±7.5 
1 (14%) 
58.3±9.7 
8.4 (6.6–9.3) 
1 (14%) 
16.0 (14.0–18.0) 
552±95
 
0.765 
0.466 
0.333 
0.646 
0.553 
0.443 
0.001
Notes: †n=11 for one treatment, n=9 for two treatments, n=14 for three treatments, and n=7 for four treatments. Values represent mean ± standard deviation or median 
(interquartile range).
Abbreviations: BCVA, best corrected visual acuity; CMT, central macular thickness; HbA1c, glycosylated hemoglobin; IOP, intraocular pressure; logMAR, Logarithm of the 
Minimum Angle of Resolution.
Characteristics of patients and visual 
outcomes in eyes treated with IVTA  
plus laser
Eyes that received more IVTA plus laser treatments had sig-
nificantly thicker maculas at baseline (Table 1 and Figure 1). 
There were no other statistically significant differences in 
measured baseline characteristics between eyes classified on 
the basis of number of treatments they received.
Predicting number of IVTA plus  
laser treatments
A total of 41 eyes (98%) had complete data. Increased 
baseline CMT was found to be a significant predictor of 
receiving three or more treatments in the binary logistic 
regression model (odds ratio 5.13, 95% confidence interval 
1.75–15.04, P=0.003 per 100 µm increase in CMT) (Table 2). 
Cox regression analysis produced a result in the same range 
as the binary logistic regression model. Similarly, a high 
baseline CMT was significantly associated with an increased 
risk of receiving three and four, but not two, treatments in 
the multinomial logistic regression model (Table 3). Age, 
gender, baseline BCVA, baseline HbA
1c
, baseline phakia and 
baseline IOP were not predictive of the number of IVTA plus 
laser treatments received.
Discussion
In this post hoc analysis of data from a prospective, ran-
domized, double-masked, placebo-controlled clinical trial 
of eyes with DME, increasing baseline CMT was strongly 
linked with requiring more IVTA plus laser treatments.11,16 
Eyes that eventually received more IVTA plus laser dur-
ing the 2 years of this study had significantly greater 
mean baseline CMT. In binary and multinomial logistic 
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Figure 1 Baseline CMT stratified with respect to number of IVTA injections combined with laser photocoagulation treatments received.
Abbreviations: CMT, central macular thickness; IVTA, intravitreal triamcinolone acetonide.
Table 2 Predictors of receiving at least two versus at least three 
intravitreal triamcinolone acetonide plus laser treatments using 
binary logistic regression analysis
Covariates Odds  
ratio
95% confidence  
interval
P-value
Baseline age 1.00 0.92–1.09 1.000
Gender 0.79 0.13–4.85 0.800
Baseline BCVA 1.01 0.93–1.10 0.787
Baseline HbA1c 0.95 0.49–1.85 0.884
Baseline phakia 2.90 0.43–19.74 0.277
Baseline IOP 0.87 0.65–1.15 0.316
Baseline CMT† 5.13 1.75–15.04 0.003
Notes: †Baseline CMT was divided by 100; odds ratios are per 100 µm change in 
CMT.
Abbreviations: BCVA, best corrected visual acuity; CMT, central macular 
thickness; HbA1c, glycosylated hemoglobin; IOP, intraocular pressure.
regression  analyses, baseline CMT was associated with 
receiving three or more treatments. No relationship was 
found between other baseline characteristics (BCVA, age, 
gender, HbA
1c
, phakia, and IOP) and the number of treat-
ments received. Notably, baseline BCVA was not a predictor 
of the number of treatments received.
The authors believe that the strong relationship found 
between a high baseline CMT and the need for IVTA retreat-
ment in the patients participating in the THUNDERBIRD 
study is representative of the routine clinical use of this drug. 
While the data were derived from a randomized controlled 
trial during which loss to follow up was low, the patients in 
the study that received a greater number of treatments did 
so because they met the retreatment criteria more frequently. 
These criteria were similar to those used in clinical practice, 
in which treatment is given at the clinician’s discretion in 
light of findings from clinical examination and imaging. 
If a clinician has a patient similar to those included in this 
study and applies similar retreatment criteria, then baseline 
CMT can be used to predict how many treatments will be 
prescribed.
This analysis is not equipped to determine why the eyes 
in this study with thicker maculas at baseline received more 
treatments than eyes with less swollen maculas. It can be 
inferred from the prospectively defined criteria that eyes that 
received multiple treatments were not responding as well to 
therapy. In this study, eyes were considered for reinjection 
plus laser 6 weeks later unless macular edema resolved, 
BCVA improved, or laser photocoagulation was no longer 
considered appropriate.
There are many potential reasons why eyes with higher 
baseline CMT might require more treatment. It might be 
that eyes with more fluid require more therapy to dry out 
the macula, ie, a high CMT is representative of more severe 
retinal dysfunction which requires more treatments to 
stabilize.17 Alternatively, in contrast to previous reports, it 
may be that DME is more likely to recur in eyes with a high 
baseline CMT.18 Irrespective of the mechanisms underlying 
the current findings, the ability to predict which patients 
will require multiple treatments has important implications 
for the risk and benefit profile of treatment. The main side 
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Table 3 Predictors of receiving two, three, or four intravitreal triamcinolone acetonide plus laser treatments compared to receiving 
one treatment using multinomial logistic regression analysis
Two treatments P-value Three treatments P-value Four treatments P-value
Baseline characteristics 
 Age 
 Female gender 
 BCVA 
 HbA1c 
 Pseudophakic, yes or no 
 IOP 
 CMT†
 
1.03 (0.93–1.15) 
0.88 (0.09–8.42) 
0.98 (0.88–1.08) 
1.17 (0.54–2.52) 
2.61 (0.20–34.60) 
1.17 (0.83–1.65) 
1.31 (0.38–4.45)
 
0.578 
0.909 
0.638 
0.690 
0.466 
0.385 
0.669
 
1.01 (0.90–1.12) 
1.86 (0.20–17.67) 
0.97 (0.87–1.08) 
0.99 (0.44–2.22) 
1.00 (0.08–13.23) 
0.94 (0.64–1.37) 
5.46 (1.45–20.57)
 
0.933 
0.590 
0.567 
0.976 
0.999 
0.752 
0.012
 
1.05 (0.89–1.23) 
0.25 (0.01–5.97) 
1.06 (0.94–1.21) 
1.11 (0.43–2.86) 
0.14 (0.00–4.66) 
0.91 (0.58–1.41) 
8.02 (1.63–39.41)
 
0.570 
0.391 
0.354 
0.833 
0.272 
0.667 
0.010
Notes: †Baseline CMT was divided by 100; odd ratios are per 100 µm change in CMT. Values represent the odds ratio (95% confidence interval).
Abbreviations: BCVA, best corrected visual acuity; CMT, central macular thickness; HbA1c, glycosylated hemoglobin; IOP, intraocular pressure.
effects of IVTA treatment are IOP elevation and accelerated 
cataract formation, both of which are dose dependent. The 
risk of cataract formation and subsequent cataract surgery 
is strongly dose related.13,19–21 Similarly, it has been shown 
that the duration of ocular hypertension is longer with higher 
doses of IVTA.14 The benefits to be gained from treatment 
in eyes with high baseline CMT should be balanced with 
the greater risk of developing adverse events.
The major weakness of this retrospective analysis 
is the relatively small number of patients available for 
analysis. A weaker correlation than that found for base-
line CMT may therefore have been missed. Conversely, 
the strength of the relationship between CMT and the 
number of IVTA plus laser treatments received should be 
viewed positively in light of the number of patients ana-
lyzed. The need for retreatment was not a prospectively 
defined outcome and the reasons for a decision to retreat 
or not were not collected from the investigators. Future 
trials should assess these factors as the ability to predict 
the number of intravitreal therapies that will be required 
before embarking on a course of therapy would be highly 
beneficial to patient care. This would be equally applicable 
to vascular endothelial growth factor inhibitors, whose 
treatment regimen is more intense with less time between 
injections than that of IVTA.
Conclusion
In summary, this analysis assessed the predictive value of 
baseline characteristics of the number of IVTA plus laser 
treatments needed to control DME in the first 2 years of a 
clinical trial. A high baseline CMT was shown to be strongly 
associated with receiving more IVTA plus laser treatments. 
No relationships were found with other commonly mea-
sured baseline characteristics. The practical implication 
of the findings of this study is that baseline CMT may be 
used as a factor when weighing up the risks and benefits of 
IVTA treatment for DME. This may become an important 
measure in the clinical decision making of the treatment of 
this disease.
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